KYSO ANTIBODY MEDICINES
Live / Registered — Registered (as of 30 Jan 2024)
What this means for you
Registered since 30 Jan 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79356463
- Registration number
- 7292415
- Mark type
- Stylized text
- Filed
- 10 Aug 2022
- Published for opposition
- 14 Nov 2023
- Registered
- 30 Jan 2024
- Attorney of record
- Max Vern
Goods and services
- Class 001 — Chemicals: Biological preparations for use in industry and science for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemical preparations for in vitro and in vivo scientific research purposes with regard to diseases; biochemical reagents used for non-medical purposes in the nature of in vitro and in vivo scientific and industrial research with regard to diseases; chemicals for use in biotechnological product development in the nature of in vitro and in vivo industrial product development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of cancer, autoimmune diseases, and inflammatory disorders
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary preparations including preparations based on antibodies, and bi- and multi-specific antibodies as well as fragments, derivatives and conjugates thereof, namely, pharmaceutical products for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical and veterinary preparations, including preparations based on antibodies, and bi- and multi- specific antibodies as well as fragments, derivatives and conjugates thereof, for the treatment of cancer, autoimmune diseases, and inflammatory disorders
- Class 042 — Scientific and technological services: Medical, scientific and biological research in the fields of antibodies, and bi- and multi-specific antibodies as well as fragments, derivatives and conjugates thereof and development of pharmaceutical products based on the same; chemical analysis; computer programming, namely, programming of computers for the collection and processing of medical data for use in medical scientific research, development and therapy and scientific research, development and therapy with antibodies and bi- and multi- specific antibodies as well as fragments, derivatives or conjugates of any of these
- Class 045 — Legal and security services: Legal services relating to the exploitation of patents and licensing of intellectual property in the field of medicine
Owner
- Genmab A/S, DK
- Genmab A/S, DK
- Genmab A/S, DK
- Genmab A/S, DK
Prosecution history
- 21 Mar 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 22 May 2024 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 01 May 2024 — FINAL DISPOSITION NOTICE SENT TO IB
- 30 Apr 2024 — FINAL DISPOSITION PROCESSED
- 30 Apr 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 30 Jan 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 30 Jan 2024 — REGISTERED-PRINCIPAL REGISTER
- 15 Jan 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 15 Jan 2024 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 15 Jan 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 15 Jan 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 14 Nov 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Nov 2023 — PUBLISHED FOR OPPOSITION
- 25 Oct 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Oct 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER